FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1287-1288 March 27, 2003 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Walsh, T. J. Related Article by Mora-Duarte, J. PubMed Citation

To the Editor: Mora-Duarte and colleagues (Dec. 19 issue)¹ fail to demonstrate that caspofungin can be considered a first-line treatment for most candida infections, because they did not use fluconazole as the comparison drug. Although Walsh, in the accompanying editorial,² mentions this limitation, it is a shame that this carefully designed trial cannot answer this most relevant question.

There is ample evidence that amphotericin B and fluconazole are equivalent in the treatment of invasive candidiasis. Fluconazole has fewer side effects, comes in an oral formulation, and is cheaper. This matter has been reviewed by the Infectious Diseases Society of America . . . [Full Text of this Article]

This article has been cited by other articles:

• Aberegg, S. K., O'Brien, J. M. Jr., Nir-Paz, R., Moses, A. E., Reboli, A. C., Wible, M., Walsh, T. J. (2007). Anidulafungin and Fluconazole for Candidiasis. NEJM 357: 1347-1348 [Full Text]  
• Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., Walsh, T. J., the Anidulafungin Study Group, (2007). Anidulafungin versus Fluconazole for Invasive Candidiasis. NEJM 356: 2472-2482 [Abstract] [Full Text]